Management

Dr. Stéphane Huberty is the founder and Chief Executive Officer of CuraVac.

He is responsible for the daily management of the company.
 
Dr. Huberty has over 20 years experience as a successful entrepreneur and manager. He also founded and is CEO of IDEAS in Belgium, a company specializing in CAD/CAM production of customized orthopaedic and normal footwear for which he was awarded the Young Entrepreneur of the Year award in 1993.

He is a medical doctor and graduate of the Catholic University of Louvain (UCL), Belgium. During his medical studies, he specialized in the use of computers in medicine and worked as a research fellow at UCLA. He has studied the research of Professor Blalock for personal reasons, as a sufferer from Myasthenia Gravis — now held under control through medication.
   Research

Professor J. Edwin Blalock is the Chief Scientific Officer of CuraVac. He is also the scientist behind this revolutionary therapeutic vaccine technology.

At CuraVac, he is responsible for the scientific research and discoveries as well as any laboratory proceedings related to this technology. It is also his role to guarantee the scientific feasibility of the product. He has been a professor of Microbiology since 1984. He is, to date, the youngest academic in the US to have earned a full professorship. He joined the University of Alabama at Birmingham (UAB) faculty in 1986 as Professor of Physiology and Biophysics. He is also adjunct Professor at the universities of Galveston, Auburn and Utrecht (NL). His areas of research centre on rational drug and vaccine design.

Professor Blalock is a renowned scientist with more than 300 scientific publications in top ranked peer reviewed scientific journals and whose work has been funded all through out his career.
Amongst his most notable discoveries is “The immune system as a sixth sense”. A discovery for which he has gained the respect of the scientific community and for which he was invited to open the Nobel Symposium in 2004.

Professor Blalock received his B.S. and Ph.D. degrees in 1971 and 1976, respectively, from the University of Florida. After one year postdoctoral training at the University of Texas Medical Branch, Galveston, he joined the faculty in 1977, and earned the title of Professor of Microbiology in 1984.

   Development

Nicolas Havelange is the Chief Operating Officer of CuraVac.

He is responsible for the supervision of process development, for the selection of subcontractors and for preclinical and clinical development at the selected subcontractors (Contract Manufacturing Organisations (CMO) and Contract Research Organisations (CRO)).

He has 12 years' experience in the red and white biotech sector, mainly in contract biomanufacturing at Henogen, a medium-sized CMO, as Process Development Director and Business Development Director. At Henogen, Nicolas participated in several vaccine development projects, from process development and GMP manufacturing to clinical trials. He has managed teams of up to 20 scientists and technicians and lead projects worth several million euros. His vaccine experience has been on projects involving three of the world’s four largest vaccine manufacturers.

Mr. Havelange holds a Master of Science in chemical engineering and in biotechnology from the University of Brussels (ULB), Belgium. He is a guest Professor in the Master of Science in Biotechnology course at Haute Ecole Lucia de Brouckere in Brussels.